RJFSA
ITRM

Raymond James Financial Services Advisors’s Iterum Therapeutics ITRM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,770
Closed -$37K – 3348
2021
Q1 		$37K Buy
+1,770
New +$42.1K ﹤0.01% 3117

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Raymond James Financial Services Advisors's ITRM Position: Q2 2021 in Review

Raymond James Financial Services Advisors sold out of Iterum Therapeutics (ITRM) in Q2 2021, closing a stake of 1,770 shares — an estimated $37K sold.

Raymond James Financial Services Advisors first reported a position in ITRM in Q1 2021 and held it in 1 quarter. The position peaked at $37K in Q1 2021. 44 funds tracked by Wall St. Rank hold ITRM as of Q2 2021.

  • Raymond James Financial Services Advisors reported no remaining Iterum Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 1,770 Iterum Therapeutics shares in Q2 2021, an estimated $37K.
  • Raymond James Financial Services Advisors first reported a position in Iterum Therapeutics in Q1 2021 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Iterum Therapeutics position peaked at $37K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.